On April 7, 2017, Eric H. Bjerkholt, Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary of Sunesis Pharmaceuticals, Inc., informed the company of his resignation from all of his positions at the company effective as of April 27, 2017, in order to pursue another opportunity. Bjerkholt will remain an employee of the company through April 27, 2017. Bjerholt has agreed in principle to continue as a consultant to the company until December 31, 2017 to assist in an orderly transition.
Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.82 USD | -95.60% | 0.00% | 0.00% |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
May. 14 | Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer | CI |
1st Jan change | Capi. | |
---|---|---|
+39.62% | 50.93B | |
-0.19% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+12.97% | 26.02B | |
-22.38% | 18.9B | |
+9.09% | 13.21B | |
+24.57% | 12.17B | |
+29.10% | 12.16B |
- Stock Market
- Equities
- VIRX Stock
- Stock
- News Viracta Therapeutics, Inc.
- Sunesis Pharmaceuticals, Inc. Announces Resignation of Eric H. Bjerkholt as Executive Vice President, Corporate Development and Finance, Chief Financial Officer